Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dr. Drew Falconer
PharmaShots Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic
In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson's and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in the US that allows patients to receive treatment from the doctor without leaving home. Shots: Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with their physicians,…
May 3, 2021
Viewpoints_Dr. Robert Koenekoop
PharmaShots Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a
In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University's Montreal Children's Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders? Shots: QR-421a demonstrated a concordant benefit in multiple measures of vision…
May 3, 2021
Viewpoints_Emmanuel Dulac
PharmaShots Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes
In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA's approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia.   Shots: The approval is based…
April 28, 2021
Viewpoints_Dr. Lara S. Sullivan and Dr. Ronald Herbst
PharmaShots Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio
In an interview with PharmaShots, Dr. Lara S. Sullivan, Chief Executive Officer, and Dr. Ronald Herbst, Chief Scientific Officer of Pyxis Oncology share insight on the importance of Series B funding and shed light on the company's strategy and near-term goals. Shots: Pyxis Oncology reported that it raised $152M in a series B on the heels of…
April 26, 2021
Viewpoints_Dr. Saoirse O'Sullivan
PharmaShots Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia
In an interview with PharmaShots, Dr. Saoirse O'Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS. Shots: The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health when affected…
April 23, 2021
Viewpoints_Douglas E. Williams
PharmaShots Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes
In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes -  extracellular vesicles that act like the body's FedEx delivery trucks to carry messengers between cells -…
April 20, 2021
Viewpoints_Dr. Kimberly Smith
PharmaShots Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on the Data Presented at CROI 2021
In an interview with PharmaShots, Dr. Kimberly Smith, Head of Global Research and Medical Strategy at ViiV Healthcare shares insights on the clinical data of GSK3640254 (GSK'254) at CROI 2021. She also highlights the key points of P-IIIb ATLAS-2M study that provide further evidence for both the once-monthly and every 2-months dosing regimens of long-acting cabotegravir and…
April 19, 2021
Load more